Ibnsina Pharma

As of June 30, 2026, Ibnsina Pharma carries a market capitalization of 11.76B, placing it among publicly traded companies globally. Its enterprise value stands at 20.68B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Ibnsina Pharma's next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, Ibnsina Pharma has 1.01B shares outstanding.

As of June 30, 2026, Ibnsina Pharma trades at a trailing price-to-earnings ratio of 10.95. The price-to-sales ratio is 0.14, and the price-to-book ratio stands at 3.75.

As of June 30, 2026, Ibnsina Pharma trades at an EV/EBITDA multiple of 5.30 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.25 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 5.88 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Ibnsina Pharma trades at an EV/FCF ratio of 15.56, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 20.68B versus a market cap of 11.76B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Ibnsina Pharma maintains a current ratio of 1.03, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 321.01, indicating elevated leverage, while an interest coverage ratio of 1.72 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Ibnsina Pharma posted a return on equity (ROE) of 38.93, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 24.44 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.93, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 24.78, useful for judging operating efficiency across full business cycles. Inventory turnover of 7.76 indicates how many times Ibnsina Pharma sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Ibnsina Pharma recorded 142.85M in income tax expense. That works out to an effective tax rate of 11.73, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.22B, leaving 1.07B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Ibnsina Pharma's stock has declined approximately 9.69% over the past 52 weeks. The 50-day moving average sits at 12.25, while the 200-day moving average is 11.67.

Over the twelve months ended June 30, 2026, Ibnsina Pharma generated 83.04B in revenue and converted that into 1.07B in net income, yielding earnings per share of 1.07. EBITDA reached 3.90B, while operating income came in at 3.52B.

As of June 30, 2026, Ibnsina Pharma holds 1.15B in cash and equivalents against 10.07B in total debt, resulting in a net debt position of 8.14B. Total book value stands at 3.14B, with working capital of 958.63M providing operational flexibility.

Ibnsina Pharma produced 563.55M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.23B in capital expenditures, free cash flow totaled -669.17M - equivalent to -0.66 per share.

Over the twelve months ended June 30, 2026, Ibnsina Pharma posted a gross margin of 8.11, reflecting its pricing power and cost economics. The operating margin of 4.23 and net profit margin of 1.29 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Ibnsina Pharma paid dividends of 0.17 per share. The dividend payout ratio of 15.66 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -5.69: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.19, meaning Ibnsina Pharma raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Ibnsina Pharma's most recent stock split took place on June 1, 2022 with a 6:7 split ratio.

As of June 30, 2026, Ibnsina Pharma has an Altman Z-Score of 2.68, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.